Phathom Pharmaceuticals
PHAT
87 hedge funds and large institutions have $317M invested in Phathom Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 30 increasing their positions, 25 reducing their positions, and 15 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 25
7% more call options, than puts
Call options by funds: $133K | Put options by funds: $124K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
5% less capital invested
Capital invested by funds: $334M → $317M (-$17.8M)
7% less funds holding
Funds holding: 94 → 87 (-7)
9.25% less ownership
Funds ownership: 77.04% → 67.79% (-9.3%)
40% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$4.3M |
| 2 |
NM
Newtyn Management
New York
|
+$1.73M |
| 3 |
BlackRock
New York
|
+$1.56M |
| 4 |
Walleye Capital
New York
|
+$1.5M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$1.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$26.8M |
| 2 |
6CM
683 Capital Management
New York
|
-$3.24M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$1.71M |
| 4 |
HF
HRT Financial
New York
|
-$585K |
| 5 |
Millennium Management
New York
|
-$558K |
PHAT Hedge Fund Activity: Q4 2022 in Review
87 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q4 2022, worth a combined $317M — down 5.3% from $334M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of PHAT and 9 opened new positions — a net loss of 6 holders — while 25 trimmed existing stakes and 30 added.
The largest buyer was Opaleye Management, opening a new position worth an estimated $4.3M. The largest seller was Deerfield Management, exiting entirely with an estimated $26.8M sold.
- 87 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q4 2022, down from 94 in Q3 2022.
- Funds reported $317M of Phathom Pharmaceuticals stock for Q4 2022, down 5.3% quarter-over-quarter.
- 9 funds opened new Phathom Pharmaceuticals positions in Q4 2022 and 15 closed out, a net change of -6 holders.
- The largest Phathom Pharmaceuticals buyer in Q4 2022 was Opaleye Management, an estimated $4.3M added.
- The largest Phathom Pharmaceuticals seller in Q4 2022 was Deerfield Management, an estimated $26.8M sold.
Based on aggregated 13F filings for Q4 2022.